CLRBCellectar Biosciences, Inc.Running, no new patients
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Waldenstrom Macroglobulinemia · Multiple Myeloma · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Lymphoplasmacytic Lymphoma · Marginal Zone Lymphoma · Mantle Cell Lymphoma · Diffuse Large B Cell Lymphoma · Central Nervous System Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 120 (planned)
- Started
- Jul 26, 2017
- Main results expected
- Jun 22, 2026
- Fully finished
- Dec 22, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A [CLOVER-1] Clinical benefit rate
Measured over: 84 days
Part B [CLOVER-WaM] Major Response Rate
Measured over: 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02952508 · record last updated 2026-03-18 · checked 2026-11-09 15:47 UTC